Stockscreener 앱 받기
7.41
0.94%
-0.07
시간 외 거래:
7.41
전일 마감가:
$7.48
열려 있는:
$7.56
하루 거래량:
264.55K
Relative Volume:
0.70
시가총액:
$270.72M
수익:
$127.70M
순이익/손실:
$-121.25M
주가수익비율:
-2.3524
EPS:
-3.15
순현금흐름:
$-120.32M
1주 성능:
+0.14%
1개월 성능:
-8.06%
6개월 성능:
-57.68%
1년 성능:
-29.76%
1일 변동 폭
$7.395
$7.63
1주일 범위
$7.395
$7.63
52주 변동 폭
$7.06
$18.75
아이테오스 Stock (ITOS) Company Profile
명칭
Iteos Therapeutics Inc
전화
857-204-4583
주소
321 ARSENAL STREET, WATERTOWN
ITOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
7.41 | 270.72M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
아이테오스 Stock (ITOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 개시 | Wells Fargo | Overweight |
| 2021-05-05 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | SVB Leerink | Outperform |
| 2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
아이테오스 주식(ITOS)의 최신 뉴스
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2% - MarketBeat
Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2% - Defense World
(ITOS) Investment Analysis and Advice - Stock Traders Daily
Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
ITOS stock touches 52-week low at $7.09 amid market challenges - MSN
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World
When (ITOS) Moves Investors should Listen - Stock Traders Daily
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully - Yahoo Finance
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decline in Short Interest - MarketBeat
(ITOS) Proactive Strategies - Stock Traders Daily
JPMorgan Chase & Co. Purchases 5,368 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 21.1% - MarketBeat
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy - MSN
iTeos Therapeutics' (ITOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
(ITOS) On The My Stocks Page - Stock Traders Daily
Barclays PLC Has $1.16 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Invivyd (NASDAQ:IVVD) vs. iTeos Therapeutics (NASDAQ:ITOS) Head-To-Head Comparison - Defense World
Iteos Therapeutics advances anti-TREM2 monoclonal antibody toward IND filing - BioWorld Online
iTeos Therapeutics Plans 2025 Data Presentation on Therapies - TipRanks
iTeos Therapeutics to raise $120 million via registered direct offering - MSN
Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Informazione.it
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025 - GlobeNewswire Inc.
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
iTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
iTeos Unveils Ambitious 2025 Cancer Drug Pipeline: Multiple Phase 2 Readouts, $684M Cash Runway - StockTitan
iTeos Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Trading (ITOS) With Integrated Risk Controls - Stock Traders Daily
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Geode Capital Management LLC - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Trimmed by Franklin Resources Inc. - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Holdings Lessened by Barclays PLC - Defense World
Reviewing Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS) - Defense World
State Street Corp Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
State Street Corp Increases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Trend Tracker for (ITOS) - Stock Traders Daily
Wells Fargo & Company Has Lowered Expectations for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo - Yahoo Finance
iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $19.00 by Analysts at Wells Fargo & Company - MarketBeat
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy - MSN
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report - BioCentury
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
Merck & Co. Calls Time On Flop TIGIT And LAG-3 Programs - News & Insights
Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright - Defense World
Wedbush Reaffirms “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
아이테오스 (ITOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):